Economic Pressures to Reduce Effort on Compliance and Improve Quality have Accelerated the Adoption of Quality by Design and PAT
The industry is looking at more holistic approaches to improve processes of bringing new products to market that can accelerate product development and lower operational costs. Quality by Design (QbD) has come relatively late to the pharmaceutical industry. In terms of quantifiable benefits, the main QbD value comes from four main areas; (1) a reduction of Cost of Goods Sold (COGS) and capital expense, (2) increased technical development productivity, (3) improved quality and lower risk, and (4) increased sales.
During this practical webinar learn how QbD principles combined with PAT technologies will facilitate and implement a robust pharmaceutical quality system according to ICH Q10 in the development and manufacturing. Practical examples will show how QbD will enable you to gain the benefits of establishing and maintaining a state of control, continual improvement, enhancing regulatory compliance and meeting quality objectives.
Leadership, outstanding processes, and culture are the ingredients for making companies successful. Technologies are just enablers to achieve that goal. This webinar explores the journey and its role in driving QbD and Pat adoption within Pharma and gives answers of some of the concepts behind the QbD concept.
Presented by
Peter J. Boogaard,
Director
Peter Boogaard is a customer first, results-driven innovated senior executive with over 25 years of significant contributions to knowledge management automation. He is founder of Industrial Lab Automation which provides services to address harmonization, integration and consolidation of business processes in Life Science development and manufacturing enabling cross-functional collaboration between research, development, quality assurance and manufacturing corporations to achieve Quality by Design (QbD) initiatives. Strong demands to help companies optimizing their processes to break their barriers across development and manufacturing resulted in teaming up with Vialis AG. Vialis is the leading provider of paperless lab for the chemical and pharmaceutical industries. Peter has published several white papers and contributes in several industry advisory boards.
